Mike Hedges welcomes announcment that New
cancer drugs to be available in Wales
A new deal with pharmaceutical company Novartis will give patients in Wales
access to new cancer drugs which are not currently routinely available in
Wales, Welsh Labour’s Deputy Minister for Health Vaughan Gething has announced.
Mike said….. ‘It is a very good news for Cancer patients in Wales that this
agreement has been reached. These type of agreements benefits both patients and
drug companies and offer opportunities to get new drugs to patients quicker. I
look forward to similar agreements in the future.
The agreement is the first if its kind in Wales and will give patients
access to the medicine everolimus - marketed under the trade names Afinitor and
Votubia - to treat certain types of advanced renal, pancreatic and breast
cancers and non-cancerous brain and kidney tumours associated with tuberous
sclerosis complex. These medicines are not currently routinely available in
Wales.
As part of the agreement Novartis will invest around £1.3m in Wales to set
up a study on breast cancer in the main oncology centres and collect outcome
data for the patients with metastatic breast cancer receiving everolimus
(Afinitor) plus exemestane (Aromasin).
In addition, the company is also investing an estimated £150,000 to support
six programmes delivering service redesign, healthcare professional education
and development, improved patient interaction and support and a tuberous
sclerosis complex clinic in Cardiff.
No comments:
Post a Comment